Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.

Abstract

OBJECTIVE Endothelin-1 (ET-1) is a vasoconstrictor mitogenic peptide whose plasma concentrations are increased in patients with peripheral arterial occlusive disease (PAOD). The aim of this study was to investigate whether changes in plasma ET-1 concentrations occur after a 4-week treatment with prostaglandin (PG) E1 in patients with intermittent… (More)

Topics

Cite this paper

@article{Mangiafico1999EffectsOA, title={Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.}, author={Roberto Antonio Mangiafico and Lorenzo Malatino and Maria Milena Santonocito and Roberto Messina and Teresa M. Attina and S Dell'arte and Francesco Sarnataro}, journal={International journal of clinical pharmacology and therapeutics}, year={1999}, volume={37 7}, pages={347-51} }